Although frontline maintenance treatment with fuzuloparib monotherapy produced a progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer, the addition of ...
Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as ...
Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback